We are a leader in developing small-molecule drugs to modulate enzymes by binding to their allosteric sites in order to address previously“undruggable” targets such as protein tyrosine phosphatases (PTPs) and KRAS. We are focused in several critical cellular pathways involved in cancer, including KRAS/SHP2, MYC and Retinoblastoma (RB), as well as immuno-oncology and tumor metabolism.
Our lead drug development programs include two clinical-stage, allosteric SHP2 inhibitors (JAB-3068 and JAB-3312). Our JAB-3068 is the second SHP2 inhibitor drug candidate globally received IND approval from the U.S. FDA to enter clinical development. We are currently evaluating the clinical efficacy of JAB-3068 in three solid tumor types in Phase IIa stage in China. We are also evaluating JAB-3312 in Phase I trials in both China and the U.S. We plan to initiate global Phase I/IIa trials to evaluate our SHP2 inhibitors either as monotherapy or in combination with each of a PD-1 antibody, a MEK inhibitor and a KRAS G12C inhibitor in the U.S. and China for a variety of solid tumors.